A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
| Status: | Archived |
|---|---|
| Conditions: | Liver Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2008 |
| End Date: | March 2011 |
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 Administered Weekly in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)
This phase I trial is studying the safety and best dose of GC33 in patients with advanced or
metastatic liver cancer.
This is a Phase I open-label dose escalation study of GC33 in patients with advanced or
metastatic HCC. This study is designed to evaluate safety, tolerability, pharmacokinetics,
and preliminary assessment of anti-tumor activity. Enrollment will proceed until a maximum
tolerated dose (MTD) and a recommended Phase II dose has been established.
We found this trial at
7
sites
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
4201 St Antoine St
Detroit, Michigan 48201
Detroit, Michigan 48201
(313) 577-1429
Wayne State University/Detroit Medical Center Founded in 1868, the Wayne State University School of Medicine...
Click here to add this to my saved trials
Click here to add this to my saved trials
Columbia Presbyterian Med Ctr On January 1, 1998, The New York Hospital publicly announced its...
Click here to add this to my saved trials
Click here to add this to my saved trials